# COVID-19: Master Protocols Evaluating Drugs and Biological Products for Treatment or Prevention:  Guidance for Industry - FDA Guidance Document

Source: https://www.globalkeysolutions.net/guidances/guidance-document/covid-19-master-protocols-evaluating-drugs-and-biological-products-for-treatment-or-prevention-guidance-for-industry/44e328fb-a98c-4db7-af9a-8b94f4ea28ea

> FDA guidance document: COVID-19: Master Protocols Evaluating Drugs and Biological Products for Treatment or Prevention:  Guidance for Industry. Issue date: May 17, 2021. Get complete insights and analysis.

---

## Details

- Title: COVID-19: Master Protocols Evaluating Drugs and Biological Products for Treatment or Prevention:  Guidance for Industry
- Communication Type: Guidance Document
- Product Type: biologics
- Office Name: Center for Drug Evaluation and Research
- Office URL: /offices/center-for-drug-evaluation-and-research/cd980d74-1cbf-4226-ba9a-9045324c236c
- Issue Date: 2021-05-17
- Last Changed: 2023-11-07
- Docket Number: <a href="https://www.regulations.gov/docket/FDA-2021-D-0409">FDA-2021-D-0409</a>

## Related Documents

- [Adjusting for Covariates in Randomized Clinical Trials for Drugs and Biological Products](https://www.globalkeysolutions.net/guidances/guidance-document/adjusting-for-covariates-in-randomized-clinical-trials-for-drugs-and-biological-products/f58b2adc-b92a-4458-b269-5346d25a8a39)
- [Evaluating Cancer Drugs in Patients with Central Nervous System Metastases:  Guidance for Industry](https://www.globalkeysolutions.net/guidances/guidance-document/evaluating-cancer-drugs-in-patients-with-central-nervous-system-metastases-guidance-for-industry/cd630104-b6ee-4993-a2ff-85effca3e866)
- [Hematologic Malignancies: Regulatory Considerations for Use of Minimal Residual Disease in Development of Drug and Biological Products for Treatment:  Guidance for Industry](https://www.globalkeysolutions.net/guidances/guidance-document/hematologic-malignancies-regulatory-considerations-for-use-of-minimal-residual-disease-in-development-of-drug-and-biological-products-for-treatment-guidance-for-industry/5e0485fc-a570-4965-bae5-05741639f886)